AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01706705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracavitary Applicator Placement
Description: MRI-compatible applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.
Study NCT01706705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: CT scan performed after implant is placed in operating room. CT scan should take about 20 minutes.
Study NCT01706705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI scan performed after implant is placed in the operating room. MRI should take about 45 minutes.
Study NCT00052078 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants received CBT.
Study NCT00052078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were treated with a placebo pill.
Study NCT02209090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maternal modified sims position
Description: Maternal Modified Sims position during at least 40 minutes for each 60 minutes
Study NCT02209090 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: maternal free positions
Description: At least 40 minutes each hour during labour
Study NCT03414177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Subspecialty Follow-up Visits
Description: Pediatric patients with persistent asthma will be recruited to compare outcomes among patients with follow-up visits managed via telemedicine vs. in-person visits.
Study NCT03714659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: Lipogems is a closed-loop system designed to break up adipose tissue into micro-fragmented adipose tissue without additives; therefore, meeting FDA requirements for minimal manipulation. A small volume of adipose tissue is harvested from the abdomen, thigh, or other location. The lipoaspirate is fed into the device through a reduction filter, and is then cleansed of blood and oil residues using a sterile saline solution. This fat-saline solution is then shaken for 30 seconds in a device containing stainless steel ball bearings, which further fragments and washes the lipoaspirate. Once the tissue is purified and fragmented, it is collected in 10cc sterile syringes and subsequently injected into the meniscus and knee joint.
Study NCT02658877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
Study NCT02658877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
Study NCT01290276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR1
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)
Study NCT01290276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR1 + MPh-IR
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
Study NCT01290276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR2
Description: Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)
Study NCT01290276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ond-PR2 +_ MPh-IR
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
Study NCT02480192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT for Menopausal Symptoms (CBT-Meno)
Description: This 12-week CBT-based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
Study NCT01815086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
Description: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
Study NCT01250925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ReNu MultiPlus® MultiPurpose Solution
Description: Contact lens care regimen
Study NCT01250925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPTI-FREE® RepleniSH®
Description: Contact Lens care regimen
Study NCT01250925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care®
Description: Contact lens care regimen
Study NCT00959686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
Study NCT00678301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Synflorix™
Description: 3 IM doses.
Study NCT00678301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Polio Sabin™
Description: 3 oral doses
Study NCT00678301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Zilbrix™ Hib
Description: 3 IM doses.
Study NCT00426127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00426127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Study NCT00426127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study NCT03610672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OD prevention/response training
Description: Participants will view a 13-minute OD prevention and response training video (available online free-of-charge). This video covers NY State's recommended curriculum for Overdose Prevention: how to prevent, identify, and respond to an OD, including information on the factors that could heighten risk for overdose (mixing drugs, changes in tolerance and drug purity, and using alone), how to respond to an overdose (rescue breathing, calling 911), and specific instructions on how and when to administer naloxone to someone who is overdosing. After the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to assemble it. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
Study NCT03610672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OD prevention/response training + PI mobile application
Description: Participants will receive the same OD intervention as those in the first arm, as well as receiving mobile phones pre-loaded with the PI App. This intervention includes daily prompts plus key components of evidence-based cognitive behavioral interventions, including Functional Analysis of Drug Use, Self-Management, and Social/Recreational Counseling and additional content on Distress Tolerance, the relationship between Peer Networks and Drug Use, and pertinent resources.
Study NCT05770960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: Oral administration of Naloxegol after waking up from the Midazolam administration during the colonoscopy.
Study NCT05770960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naloxegol
Description: Oral administration of Naloxegol after waking up from the Midazolam administration during the colonoscopy.
Study NCT05770960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: codeine phosphate
Description: Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.
Study NCT05770960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: codeine phosphate
Description: Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.
Study NCT05770960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Oral administration of siripus simplex syrup after waking up from the Midazolam administration during the colonoscopy.
Study NCT01601522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peanut protein
Description: 500 mg
Study NCT01601522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peanut protein
Description: 500 mg
Study NCT01601522 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Oat flour
Description: 500 mg Oat flour
Study NCT01601522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid
Study NCT01277692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 10mg
Description: single dose once daily
Study NCT01277692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 30mg
Description: single dose once daily
Study NCT01277692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 100mg
Description: single dose once daily
Study NCT01277692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 200mg
Description: single dose once daily
Study NCT01277692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 10mg
Description: repeat dose once daily for 7 days
Study NCT01277692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 dose to be determined up to 100mg
Description: repeat dose once daily for 7 days
Study NCT01277692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 5mg
Description: single dose in HCV infected patients
Study NCT01277692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 30mg
Description: single dose in HCV infected patients
Study NCT01277692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2236805 100mg
Description: single dose in HCV infected patients
Study NCT03120468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate and N-Acetyl Cysteine
Description: Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
Study NCT03120468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate and Placebo
Description: Topiramate up to 200 mg/day and Placebo for 12 weeks
Study NCT01689857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scarclinic™ Thin
Description: Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
Study NCT01689857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scarclinic™ Normal
Description: Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
Study NCT02639455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
Study NCT04052815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes prevention program culturally tailored
Description: Diabetes prevention Program (DPP) as specified by the CDC, physical activity prior to DPP sessions, motivational interviewing individual and in group. Culturally tailored nutrition tips and recipes.
Study NCT00335140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.
Study NCT00335140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
Study NCT00335140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
Study NCT00335140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
Study NCT00335140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture
Study NCT00335140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: 100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
Study NCT00335140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
Study NCT04849767 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire about socio-behavioral items and conditions of vulnerability. interview with female to male transgender person will be about life conditions, trajectory of the medical transition from female to male and actual medical following of the transition, migration trajectory and condition of HIV acquisition.
Study NCT00919191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin gel
Description: Tretinoin gel 0.04% used once daily in a split-face model
Study NCT00919191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl peroxide
Description: Adapalene .1% and Benzoyl peroxide 2.5%
Study NCT03808142 — intervention group
Intervention type: OTHER
Intervention: myBETAapp
Description: Patients choosing to use the myBETAapp were required to insert the Mixject number from their prescribed Betaferon box, which serves as an opening key for the app. Obtaining a new Betaferon box and obtaining a new Mixject number was not interfere with the process of continuously allocating data to a single patient; each patient had a unique personal identifier in the database. All data recorded in the myBETAapp including demographic and injection-related data were stored in the database once the mobile device was connected to the internet.
Study NCT03808142 — intervention group
Intervention type: OTHER
Intervention: PEAK
Description: Peak is an application that aims at helping its users to challenge their brains and keep them sharp.
Study NCT03808142 — intervention group
Intervention type: DRUG
Intervention: Betaferon, BAY86-5046
Description: Injection
Study NCT03808142 — intervention group
Intervention type: DEVICE
Intervention: BETACONNECT
Description: BETACONNECT automatically records and stores injection-related details including injection time, speed, and depth upon every injection.
Study NCT00767429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fall risk detector
Description: fall risk detector: stumbles, specific fall related movements, falls
Study NCT01753726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm stretching.
Description: A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.
Study NCT01753726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: Disconnected ultrasound was used for the 7 min as sham treatment
Study NCT03812029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonafexor
Description: Oral tablets
Study NCT03812029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT01128270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate environmental dose
Description: On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
Study NCT01128270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate environmental dose
Description: Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
Study NCT01128270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate therapeutic dose
Description: Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
Study NCT01128270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate therapeutic dose
Description: Subject is given 25 mg/kg of Chloral Hydrate for five nights.
Study NCT01269151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis (Ranibizumab)
Description: Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
Study NCT03738475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: 8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
Study NCT03738475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously on days 1 and 8.
Study NCT05156151 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Relex-Smile
Study NCT03157297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARVEL algorithm
Description: Software download into implanted Micra device
Study NCT01923467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Quit stop smoking program
Description: This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
Study NCT01923467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patches 21 mg
Description: Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
Study NCT01539369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day
Description: Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided.
Study NCT01539369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day
Description: Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided.
Study NCT03733353 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbial
Study NCT01329770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)
Description: * Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)~* Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks
Study NCT01329770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
Study NCT03018275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Roseomonas mucosa
Description: R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.